Resverlogix (TSE:RVX) Announces Quarterly Earnings Results

Resverlogix (TSE:RVX) issued its quarterly earnings results on Friday. The biotechnology company reported C$0.01 earnings per share for the quarter, FiscalAI reports.

Resverlogix Trading Down 5.0%

TSE RVX traded down C$0.01 during trading hours on Friday, hitting C$0.10. 4,000 shares of the company’s stock were exchanged, compared to its average volume of 31,323. The business’s 50 day moving average is C$0.11 and its 200-day moving average is C$0.10. Resverlogix has a 12-month low of C$0.04 and a 12-month high of C$0.30. The firm has a market capitalization of C$30.04 million, a P/E ratio of -3.17 and a beta of 0.72. The company has a debt-to-equity ratio of -81.94, a quick ratio of 0.04 and a current ratio of 0.04.

About Resverlogix

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.